Metraipolis › archive › dc_f5e39b140d0d
Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42577818
- DOI
- 10.3389/fonc.2026.1875861
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T03:54:04.085Z
- SHA-256 of the archived text
1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a- Stable URL of this page
https://metraipolis.com/documento/dc_f5e39b140d0d
How to cite
Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818 — Europe PMC (en), https://europepmc.org/article/MED/42577818 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f5e39b140d0d (Metraipolis archive dc_f5e39b140d0d, sha256 1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a)
BibTeX
@misc{dcf5e39b140d0d,
title = {Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42577818},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f5e39b140d0d; sha256 1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42577818. Agents can read the archived copy with the MCP tool read_document.